Abstract

Cerebellar ataxias are characterized by a progressive decline in motor coordination, but the specific output circuits and underlying pathological mechanism remain poorly understood. Through cell-type-specific manipulations, we discovered a novel GABAergic Purkinje cell (PC) circuit in the cerebellar IV/V lobe that projected to CaMKIIα+ neurons in the fastigial nucleus (FN), which regulated sensorimotor coordination. Furthermore, transcriptomics profiling analysis revealed various cerebellar neuronal identities, and we validated that biorientation defective 1 (BOD1) played an important role in the circuit of IV/V lobe to FN. BOD1 deficit in PCs of IV/V lobe attenuated the excitability and spine density of PCs, accompany with ataxia behaviors. Instead, BOD1 enrichment in PCs of IV/V lobe reversed the hyperexcitability of CaMKIIα+ neurons in the FN and ameliorated ataxia behaviors in L7-Cre; BOD1f/f mice. Together, these findings further suggest that specific regulation of the cerebellar IV/V lobePCs → FNCaMKIIα+ circuit might provide neuromodulatory targets for the treatment of ataxia behaviors.

Details

Title
BOD1 regulates the cerebellar IV/V lobe-fastigial nucleus circuit associated with motor coordination
Author
Liu, Xiu-Xiu 1 ; Chen, Xing-Hui 2 ; Zheng, Zhi-Wei 3 ; Jiang, Qin 3 ; Li, Chen 1 ; Yang, Lin 2 ; Chen, Xiang 1 ; Mao, Xing-Feng 1 ; Yuan, Hao-Yang 3   VIAFID ORCID Logo  ; Feng, Li-Li 1 ; Jiang, Quan 4 ; Shi, Wei-Xing 5 ; Sasaki, Takuya 6 ; Fukunaga, Kohji 6 ; Chen, Zhong 4   VIAFID ORCID Logo  ; Han, Feng 7 ; Lu, Ying-Mei 8 

 Nanjing Medical University, Key Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984) 
 Nanjing Medical University, Department of Physiology, School of Basic Medical Sciences, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Zhejiang University, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Nanjing Medical University, Department of Physiology, School of Basic Medical Sciences, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984) 
 Zhejiang University, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Loma Linda University School of Pharmacy, Department of Pharmaceutical and Administrative Sciences, Loma Linda, USA (GRID:grid.43582.38) (ISNI:0000 0000 9852 649X); Loma Linda University School of Medicine, Department of Basic Sciences, Loma Linda, USA (GRID:grid.43582.38) (ISNI:0000 0000 9852 649X) 
 Graduate School of Pharmaceutical Sciences, Tohoku University, Department of Pharmacology, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
 Nanjing Medical University, Key Laboratory of Cardiovascular & Cerebrovascular Medicine, Drug Target and Drug Discovery Center, School of Pharmacy, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); the Affiliated Brain Hospital of Nanjing Medical University, Institute of Brain Science, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Nanjing Medical University, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Suzhou, China (GRID:grid.440227.7) (ISNI:0000 0004 1758 3572) 
 Nanjing Medical University, Department of Physiology, School of Basic Medical Sciences, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); the Affiliated Brain Hospital of Nanjing Medical University, Institute of Brain Science, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2671804386
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.